nPhase.ai also introduces its agentic statistical computing environment (SCE) to reduce the time from raw study data to submission-ready outputs by 75% with 80% fewer resources

ATLANTIC BEACH, Fla.: nPhase, Inc., the clinical research technology company known for REDCap Cloud, today launched nPhase.ai, the life sciences industry’s first enterprise platform for end-to-end clinical data management. The company also introduces nPhase.ai SCE (Statistical Computing Environment). An AI-native platform built on Clinical Data Interchange Standards Consortium (CDISC) standards, the governed platform transforms raw clinical trial data into submission-ready outputs at least 4x faster with 80% fewer resources.

Clinical trial data has outgrown existing systems both in volume and complexity. A recent Tufts CSDD analysis found the average phase III protocol now generates nearly six million data points. Most of that volume arrives from unstructured data systems that were never designed to interoperate, leaving sponsors with data that is difficult to reuse or be leveraged by AI.

“Clinical data has never been more complex, with information flowing from dozens of systems, with different formats, structures, and types,” said Scott Climes, CEO of nPhase, Inc. “nPhase.ai addresses this pervasive challenge by transforming disparate clinical data into high-fidelity, harmonized datasets in near real-time, enabling faster analytics, better insights, and more informed decision-making. Now, with SCE, we are combining the speed and intelligence of AI with human oversight to make clinical data truly AI-ready from source to submission.”

nPhase.ai SCE automatically converts raw study data into the regulatory artifacts required for submission through one, governed, and traceable pipeline. It compresses a process that typically takes four or more months to weeks. Every week gained between last-patient-last-visit and submission not only accelerates treatments to patients but also gives sponsors additional market exclusivity.

nPhase.ai SCE provides the following key benefits:

• Faster submissions filing. Agentic generation of submission assets with more than 90% of raw study data mapped to CDISC standards with no human intervention helps accelerate study sponsors’ pipeline throughput, time to market and revenue.
• Economics that make small-population research fundable. nPhase.ai SCE helps improve the unit economics of trials as the cost of turning trial data into a submission is typically driven by protocol complexity rather than patient count.
• Federated data sharing with enterprise compliance and governance to scale AI. Sharing clinical data today typically requires rigorous work, compliance reviews and presents a new liability, slowing progress and stalling most life sciences AI programs before piloted. Federation removes this burden and offers governed access with compliance enforced at the record level.

“CDISC standards exist to make clinical data usable across systems and sponsors," said Chris Decker, President and CEO of CDISC. "CDISC’s transformation to Machine-readable standards is the foundation that makes automation of clinical data workflows possible. We're glad to see the industry building tools that rely on that foundation.”

Visit nPhase at SCDM 2026, Sept. 14–17, Raleigh, N.C. (booth 525), and DPHARM, Sept. 15–16, Boston (booth 407). Or sign up for a personal demo here.

About nPhase, Inc.

nPhase, Inc. builds clinical research technology that connects clinical trial and real-world data into a single foundation for clinical decision making. Its enterprise platform, nPhase.ai enables the application of AI at every stage of the clinical data layer, from acquisition through submission, for pharmaceutical sponsors and CROs. Its first products include nPhase.ai SCE and a unified data management system (UDMS). REDCap Cloud EDC serves small and mid-size sponsors, non-profit and academic research organizations, MedTech studies and real-world data programs. More at www.nphase.ai and www.redcapcloud.com.

Fonte: Business Wire